

1. Mystakidou K, Parpa E, Katsouda E, et al. The role of physical and psychological symptoms in desire for death: a study of terminally ill cancer patients. *Psychooncology* 2006;15:355–360.
2. Prue G, Rankin J, Allen J, et al. Cancer-related fatigue: A critical appraisal. *Eur J Cancer* 2006;42:846–863.
3. Braun IM, Greenberg DB, Pirl WF. Evidenced-based report on the occurrence of fatigue in long-term cancer survivors. *J Natl Compr Canc Netw* 2008;6:347–354.
4. Goedendorp MM, Gielissen MF, Verhagen CA, et al. Development of fatigue in cancer survivors: a prospective follow-up study from diagnosis into the year after treatment. *J Pain Symptom Manage* 2013;45:213–222.
5. Ness S, Kokal J, Fee-Schroeder K, et al. Concerns across the survivorship trajectory: results from a survey of cancer survivors. *Oncol Nurs Forum* 2013;40:35–42.
6. Campos MP, Hassan BJ, Riechelmann R, et al. Cancer-related fatigue: a practical review. *Ann Oncol* 2011;22:1273–1279.
7. Dhruva A, Aouizerat BE, Cooper B, et al. Differences in morning and evening fatigue in oncology patients and their family caregivers. *Eur J Oncol Nurs* 2013;17:841–848.
8. Langston B, Armes J, Levy A, et al. The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. *Support Care Cancer* 2013;21:1761–1771.
9. Peters ME, Goedendorp MM, Verhagen CA, et al. Severe fatigue during the palliative treatment phase of cancer: an exploratory study. *Cancer Nurs* 2014;37:139–145.
10. Weis J. Cancer-related fatigue: prevalence, assessment and treatment strategies. *Expert Rev Pharmacoecon Outcomes Res* 2011;11:441–446.
11. Chen E, Khan L, Zhang L, et al. Symptom clusters in patients with bone metastases—a reanalysis comparing different statistical methods. *Support Care Cancer* 2012;20:2811–2820.
12. Kirkova J, Aktas A, Walsh D, et al. Cancer symptom clusters: clinical and research methodology. *J Palliat Med* 2011;14:1149–1166.
13. Thavarajah N, Chen E, Zeng L, et al. Symptom clusters in patients with metastatic cancer: a literature review. *Expert Rev Pharmacoecon Outcomes Res* 2012;12:597–604.
14. Thomas BC, Waller A, Malhi RL, et al. A longitudinal analysis of symptom clusters in cancer patients and their sociodemographic predictors. *J Pain Symptom Manage* 2013;47:566–578.
15. Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the management of fatigue. *Oncology (Williston Park, N.Y.)* 1998;12:369–377.
16. Barsevick AM, Irwin MR, Hinds P, et al. Recommendations for high-priority research on cancer-related fatigue in children and adults. *J Natl Cancer Inst* 2013;105:1432–1440.
17. Piper BF, Cella D. Cancer-related fatigue: definitions and clinical subtypes. *J Natl Compr Canc Netw* 2010;8:958–966.
18. Mallinson T, Cella D, Cashy J, et al. Giving meaning to measure: linking self-reported fatigue and function to performance of everyday activities. *J Pain Symptom Manage* 2006;31:229–241.
19. Escalante CP, Manzullo EF. Cancer-related fatigue: the approach and treatment. *J Gen Intern Med* 2009;24:S412–S416.
20. Minton O, Stone PC. A comparison of cognitive function, sleep and activity levels in disease-free breast cancer patients with or without cancer-related fatigue syndrome. *BMJ Support Palliat Care* 2013;2:231–238.
21. Peters ME, Goedendorp MM, Verhagen SA, et al. Exploring the contribution of psychosocial factors to fatigue in patients with advanced incurable cancer. *Psychooncology* 2014;23:773–779.
22. Daniels LA, Oerlemans S, Krol AD, et al. Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity. *Br J Cancer* 2014;110:868–874.
23. Wang XS, Zhao F, Fisch MJ, et al. Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. *Cancer* 2014;120:425–432.
24. Lindqvist O, Widmark A, Rasmussen BH. Meanings of the phenomenon of fatigue as narrated by 4 patients with cancer in palliative care. *Cancer Nurs* 2004;27:237–243.
25. Davis MP, Goforth H. Fighting insomnia and battling lethargy: the yin and yang of palliative care. *Curr Oncol Rep* 2014;16:377.
26. Fleming L, Randell K, Harvey CJ, et al. Does cognitive behaviour therapy for insomnia reduce clinical levels of fatigue, anxiety and depression in cancer patients? *Psychooncology* 2014;23:679–684.
27. Valdes-Stauber J, Vietz E, Kilian R. The impact of clinical conditions and social factors on the psychological distress of cancer patients: an explorative study at a consultation and liaison service in a rural general hospital. *BMC Psychiatry* 2013;13:226.
28. Nishiura M, Tamura A, Nagai H, et al. Assessment of sleep disturbance in lung cancer patients: Relationship between sleep disturbance and pain, fatigue, quality of life, and psychological distress. *Palliat Support Care* 2014;1–7.
29. Bormeman T, Piper BF, Koczywas M, et al. A qualitative analysis of cancer-related fatigue in ambulatory oncology. *Clin J Oncol Nurs* 2012;16:E26–E32.
30. Wu HS, McSweeney M. Cancer-related fatigue: “It’s so much more than just being tired”. *Eur J Oncol Nurs* 2007;11:117–125.
31. Scott JA, Lasch KE, Barsevick AM, et al. Patients’ experiences with cancer-related fatigue: a review and synthesis of qualitative research. *Oncol Nurs Forum* 2011;38:E191–E203.
32. Lukkahatai N, Saligan LN. Association of catastrophizing and fatigue: a systematic review. *J Psychosom Res* 2013;74:100–109.
33. Menshadi N, Bar-Tal Y, Barnoy S. The relationship between learned resourcefulness and cancer-related fatigue in patients with non-Hodgkin lymphoma. *Oncol Nurs Forum* 2013;40:133–138.
34. Modlinska A, Kowalik B, Buss T, et al. Strategy of coping with end-stage disease and cancer-related fatigue in terminally ill patients. *Am J Hosp Palliat Care* 2013. [Epub ahead of print]
35. Hauser K, Rybicki L, Walsh D. What’s in a Name? Word descriptors of cancer-related fatigue. *Palliat Med* 2010;24:724–730.
36. Sadler IJ, Jacobsen PB, Booth-Jones M, et al. Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue. *J Pain Symptom Manage* 2002;23:406–416.
37. Tcheckmedyan NS, Kallich J, McDermott A, et al. The relationship between psychological distress and cancer-related fatigue. *Cancer* 2003;98:198–203.
38. de Raaf PJ, de Klerk C, Timman R, et al. Systematic monitoring and treatment of physical symptoms to alleviate fatigue in patients with advanced cancer: a randomized controlled trial. *J Clin Oncol* 2013;31:716–723.
39. Donovan KA, McGinty HL, Jacobsen PB. A systematic review of research using the diagnostic criteria for cancer-related fatigue. *Psychooncology* 2013;22:737–744.
40. Reuter K, Harter M. The concepts of fatigue and depression in cancer. *Eur J Cancer Care (Engl)* 2004;13:127–134.
41. Traeger L, Braun IM, Greer JA, et al. Parsing depression from fatigue in patients with cancer using the fatigue symptom inventory. *J Pain Symptom Manage* 2011;42:52–59.
42. Scialla SJ, Cole RP, Bednarz L. Redefining cancer-related asthenia-fatigue syndrome. *J Palliat Med* 2006;9:866–872.
43. Minton O, Alexander S, Stone PC. Identification of factors associated with cancer related fatigue syndrome in disease-free breast cancer patients after completing primary treatment. *Breast Cancer Res Treat* 2012;136:513–520.
44. Brown LF, Kroenke K. Cancer-related fatigue and its associations with depression and anxiety: a systematic review. *Psychosomatics* 2009;50:440–447.
45. Bower JE. Fatigue, brain, behavior, and immunity: summary of the 2012 Named Series on fatigue. *Brain Behav Immun* 2012;26:1220–1223.
46. Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. *Brain Behav Immun* 2013;30:S48–S57.
47. Berger AM, Abernethy AP, Atkinson A, et al. Cancer-related fatigue. *J Natl Compr Cancer Netw* 2010;8:904–931.
48. Efficace F, Breccia M, Saussele S, et al. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group. *Ann Hematol* 2012;91:1371–1381.
49. Hagiwara M, Borker R, Oster G. Economic burden of adverse events in patients with metastatic renal cell carcinoma. *Clin Ther* 2013;35:1955–1963.
50. Neeffes EC, van der Vorst MJ, Blauwhoff-Buskermolen S, et al. Aiming for a better understanding and management of cancer-related fatigue. *Oncologist* 2013;18:1135–1143.
51. Wood LJ, Weymann K. Inflammation and neural signaling: etiologic mechanisms of the cancer treatment-related symptom cluster. *Curr Opin Support Palliat Care* 2013;7:54–59.
52. Giacalone A, Quitadamo D, Zanet E, et al. Cancer-related fatigue in the elderly. *Support Care Cancer* 2013;21:2899–2911.
53. Trudel-Fitzgerald C, Savard J, Ivers H. Evolution of cancer-related symptoms over an 18-month period. *J Pain Symptom Manage* 2013;45:1007–1018.
54. Poghosyan H, Sheldon LK, Leveille SC, et al. Health-related quality of life after surgical treatment in patients with non-small cell lung cancer: a systematic review. *Lung Cancer (Amsterdam, Netherlands)* 2013;81:11–26.
55. Karthikeyan G, Jumrani D, Prabhu R, et al. Prevalence of fatigue among cancer patients receiving various anticancer therapies and its impact on quality of life: a cross-sectional study. *Indian J Palliat Care* 2012;18:165–175.
56. Bruera E. Cancer-related fatigue: a multidimensional syndrome. *J Support Oncol* 2010;8:175–176.
57. Horneber M, Fischer I, Dimeo F, et al. Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment. *Dtsch Arztebl Int* 2012;109:161–171.
58. Mortimer JE, Barsevick AM, Bennett CL, et al. Studying cancer-related fatigue: report of the NCCN scientific research committee. *J Natl Compr Cancer Netw* 2010;8:1331–1339.
59. Seo Y, Oh H, Seo W. Causal relationships among factors associated with cancer-related fatigue. *Eur J Oncol Nurs* 2010;14:380–386.
60. Oh HS, Seo WS. Systematic review and meta-analysis of the correlates of cancer-related fatigue. *Worldviews Evid Based Nurs* 2011;8:191–201.
61. Purcell A, Fleming J, Bennett S, et al. A multidimensional examination of correlates of fatigue during radiotherapy. *Cancer* 2010;116:529–537.
62. Zick SM, Sen A, Han-Markey TL, et al. Examination of the association of diet and persistent cancer-related fatigue: a pilot study. *Oncol Nurs Forum* 2013;40:E41–E49.

63. Strasser F, Palmer JL, Schover LR, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. *Cancer* 2006;107:2949–2957.
64. Gould DW, Lahart I, Carmichael AR, et al. Cancer cachexia prevention via physical exercise: molecular mechanisms. *J Cachexia Sarcopenia Muscle* 2013;4:111–124.
65. Pertl M, Hevey D, Collier S, et al. Predictors of fatigue in cancer patients before and after chemotherapy. *J Health Psychol* 2013;19:699–710.
66. Neil SE, Klika RJ, Garland SJ, et al. Cardiorespiratory and neuromuscular deconditioning in fatigued and non-fatigued breast cancer survivors. *Support Care Cancer* 2013;21:873–881.
67. Reyes-Gibby CC, Swartz MD, Yu X, et al. Symptom clusters of pain, depressed mood, and fatigue in lung cancer: assessing the role of cytokine genes. *Support Care Cancer* 2013;21:3117–3125.
68. Saligan LN, Kim HS. A systematic review of the association between immunogenomic markers and cancer-related fatigue. *Brain Behav Immun* 2012;26:830–848.
69. Lukkahatai N, Patel S, Gucek M, et al. Proteomic serum profile of fatigued men receiving localized external beam radiation therapy for non-metastatic prostate cancer. *J Pain Symptom Manage* 2014;47:748–756.e4.
70. Light KC, Agarwal N, Jacob E, et al. Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome. *Psychoneuroendocrinology* 2013;38:2983–2995.
71. Schubert C, Hong S, Natarajan L, et al. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. *Brain Behav Immun* 2007;21:413–427.
72. Liu L, Mills PJ, Rissling M, et al. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. *Brain Behav Immun* 2012;26:706–713.
73. Payne JK. Altered circadian rhythms and cancer-related fatigue outcomes. *Integr Cancer Ther* 2011;10:221–233.
74. Piper BF, Lindsey AM, Dodd MJ. Fatigue mechanisms in cancer patients: developing nursing theory. *Oncol Nurs Forum* 1987;14:17–23.
75. Irvine D, Vincent L, Graydon JE, et al. The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. *Cancer Nurs* 1994;17:367–378.
76. Winningham ML. Strategies for managing cancer-related fatigue syndrome: a rehabilitation approach. *Cancer* 2001;92:988–997.
77. Aistars J. Fatigue in the cancer patient: a conceptual approach to a clinical problem. *Oncol Nurs Forum* 1987;14:25–30.
78. Rhoten D. Fatigue and the postsurgical patient. In: Norris CM, ed. *Concept Clarification in Nursing*. Rockville, MD: Aspen Systems Corp.; 1982:277–300.
79. Glaus A. Fatigue in patients with cancer. Analysis and assessment. *Recent Results Cancer Res* 1998;145:1–XI, 1–172.
80. Olson K. A new way of thinking about fatigue: a reconceptualization. *Oncol Nurs Forum* 2007;34:93–99.
81. Miller AH, Ancoli-Israel S, Bower JE, et al. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. *J Clin Oncol* 2008;26:971–982.
82. Lee BN, Dantzer R, Langley KE, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. *Neuroimmunomodulation* 2004;11:279–292.
83. Payne J. A neuroendocrine-based regulatory fatigue model. *Biol Res Nurs* 2004;6:141–150.
84. Olson K, Turner AR, Courmeya KS, et al. Possible links between behavioral and physiological indices of tiredness, fatigue, and exhaustion in advanced cancer. *Support Care Cancer* 2008;16:241–249.
85. Al-Majid S, Gray DP. A biobehavioral model for the study of exercise interventions in cancer-related fatigue. *Biol Res Nurs* 2009;10:381–391.
86. Luthy C, Cedraschi C, Pugliesi A, et al. Patients' views about causes and preferences for the management of cancer-related fatigue—a case for non-congruence with the physicians? *Support Care Cancer* 2011;19:363–370.
87. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. *Semin Hematol* 1997;34:4–12.
88. Hockenberry-Eaton M, Hinds PS. Fatigue in children and adolescents with cancer: evolution of a program of study. *Semin Oncol Nurs* 2000;16:261–272.
89. Knowles G, Borthwick D, McNamara S, et al. Survey of nurses' assessment of cancer-related fatigue. *Eur J Cancer Care (Engl)* 2000;9:105–113.
90. Hilarius DL, Kloeg PH, van der Wall E, et al. Cancer-related fatigue: clinical practice versus practice guidelines. *Support Care Cancer* 2011;19:531–538.
91. Curt GA. Impact of fatigue on quality of life in oncology patients. *Semin Hematol* 2000;37:14–17.
92. Pertl MM, Quigley J, Hevey D. 'I'm not complaining because I'm alive': barriers to the emergence of a discourse of cancer-related fatigue. *Psychol Health* 2014;29:141–161.
93. Borneman T, Koczywas M, Sun V, et al. Effectiveness of a clinical intervention to eliminate barriers to pain and fatigue management in oncology. *J Palliat Med* 2011;14:197–205.
94. Passik SD, Kirsh KL, Donaghy K, et al. Patient-related barriers to fatigue communication: initial validation of the fatigue management barriers questionnaire. *J Pain Symptom Manage* 2002;24:481–493.
95. Komatsu H, Watanabe C, Yagasaki K, et al. Validation of the Japanese version of the Fatigue Barriers Scale (JFBS). *Int J Palliat Nurs* 2013;19:503–509.
96. Hoffman AJ, von Eye A, Gift AG, et al. The development and testing of an instrument for perceived self-efficacy for fatigue self-management. *Cancer Nurs* 2011;34:167–175.
97. Alexander S, Minton O, Stone PC. Evaluation of screening instruments for cancer-related fatigue syndrome in breast cancer survivors. *J Clin Oncol* 2009;27:1197–1201.
98. Strasser F, Muller-Kaser I, Dietrich D. Evaluating cognitive, emotional, and physical fatigue domains in daily practice by single-item questions in patients with advanced cancer: a cross-sectional pragmatic study. *J Pain Symptom Manage* 2009;38:505–514.
99. Davis KM, Lai JS, Hahn EA, et al. Conducting routine fatigue assessments for use in clinical oncology practice: patient and provider perspectives. *Support Care Cancer* 2008;16:379–386.
100. Smith SK, Rowe K, Abernethy AP. Use of an electronic patient-reported outcome measurement system to improve distress management in oncology. *Palliat Support Care* 2014;12:69–73.
101. Lai JS, Cella D, Choi S, et al. How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. *Arch Phys Med Rehabil* 2011;92:S20–S27.
102. Butt Z, Wagner LJ, Beaumont JL, et al. Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. *J Pain Symptom Manage* 2008;35:20–30.
103. Cancer-related fatigue (version 1.2014). National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf.
104. Banthia R, Malcarne VL, Roesch SC, et al. Correspondence between daily and weekly fatigue reports in breast cancer survivors. *J Behav Med* 2006;29:269–279.
105. Sobel-Fox RM, McSorley AM, Roesch SC, et al. Assessment of daily and weekly fatigue among African American cancer survivors. *J Psychosoc Oncol* 2013;31:413–429.
106. Mota DD, Pimenta CA. Self-report instruments for fatigue assessment: a systematic review. *Res Theory Nurs Pract* 2006;20:49–78.
107. Whitehead L. The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. *J Pain Symptom Manage* 2009;37:107–128.
108. Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: a systematic review. *J Clin Oncol* 2006;24:1459–1473.
109. Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). *Ann Oncol* 2009;20:17–25.
110. Seyidova-Khosknabi D, Davis MP, Walsh D. Review article: a systematic review of cancer-related fatigue measurement questionnaires. *Am J Hosp Palliat Care* 2011;28:119–129.
111. Jean-Pierre P, Figueroa-Moseley CD, Kohli S, et al. Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. *Oncologist* 2007;12:11–21.
112. Agasi-Idenburg C, Velthuis M, Wittink H. Quality criteria and user-friendliness in self-reported questionnaires on cancer-related fatigue: a review. *J Clin Epidemiol* 2010;63:705–711.
113. Barsevick AM, Cleeland CS, Manning DC, et al. ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials. *J Pain Symptom Manage* 2010;39:1086–1099.
114. Hacker ED, Ferrans CE. Ecological momentary assessment of fatigue in patients receiving intensive cancer therapy. *J Pain Symptom Manage* 2007;33:267–275.
115. Chevillat AL. Cancer-related fatigue. *Phys Med Rehabil Clin N Am* 2009;20:405–416.
116. Nourissat A, Vasson MP, Merrouche Y, et al. Relationship between nutritional status and quality of life in patients with cancer. *Eur J Cancer* 2008;44:1238–1242.
117. Escalante CP, Kallen MA, Valders RU, et al. Outcomes of a cancer-related fatigue clinic in a comprehensive cancer center. *J Pain Symptom Manage* 2010;39:691–701.
118. Kwekkeboom KL, Abbott-Anderson K, Cherwin C, et al. Pilot randomized controlled trial of a patient-controlled cognitive-behavioral intervention for the pain, fatigue, and sleep disturbance symptom cluster in cancer. *J Pain Symptom Manage* 2012;44:810–822.
119. Radbruch L, Strasser F, Elsner F, et al. Fatigue in palliative care patients — an EAPC approach. *Palliat Med* 2008;22:13–32.
120. Dy SM, Lorenz KA, Naeim A, et al. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. *J Clin Oncol* 2008;26:3886–3895.
121. Kangas M, Bovbjerg DH, Montgomery GH. Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. *Psychol Bull* 2008;134:700–741.
122. Minton O, Richardson A, Sharpe M, et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. *J Natl Cancer Inst* 2008;100:1155–1166.
123. Jacobsen PB, Donovan KA, Vadaparampil ST, et al. Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. *Health Psychol* 2007;26:660–667.
124. Goedendorp MM, Gielissen MF, Verhagen CA, et al. Psychosocial interventions for reducing fatigue during cancer treatment in adults. *Cochrane Database Syst Rev* 2009:CD006953.

125. Mitchell SA. Cancer-related fatigue: state of the science. *PM R* 2010;2:364–383.
126. Minton O, Richardson A, Sharpe M, et al. Drug therapy for the management of cancer-related fatigue. *Cochrane Database Syst Rev* 2010;CD006704.
127. Minton O, Richardson A, Sharpe M, et al. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. *J Pain Symptom Manage* 2011;41:761–767.
128. Kwekkeboom KL, Cherwin CH, Lee JW, et al. Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. *J Pain Symptom Manage* 2010;39:126–138.
129. Arnold M, Taylor NF. Does exercise reduce cancer-related fatigue in hospitalised oncology patients? A systematic review. *Onkologie* 2010;33:625–630.
130. Finnegan-John J, Molassiotis A, Richardson A, et al. A systematic review of complementary and alternative medicine interventions for the management of cancer-related fatigue. *Integr Cancer Ther* 2013;12:276–290.
131. Minton O, Berger A, Barsevick A, et al. Cancer-related fatigue and its impact on functioning. *Cancer* 2013;119:2124–2130.
132. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. *Cochrane Database Syst Rev* 2012;11:CD006145.
133. Puetz TW, Herring MP. Differential effects of exercise on cancer-related fatigue during and following treatment: a meta-analysis. *Am J Prev Med* 2012;43:e1–e24.
134. Brown JC, Huedo-Medina TB, Pescatello LS, et al. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2011;20:123–133.
135. Mitchell SA, Hoffman AJ, Clark JC, et al. Putting Evidence into Practice (PEP): A 2014 update of evidence-based interventions for cancer-related fatigue during and following treatment. *Clin J Oncol Nurs* (In press).
136. Breitbart W, Alici Y. Pharmacologic treatment options for cancer-related fatigue: current state of clinical research. *Clin J Oncol Nurs* 2008;12:27–36.
137. Capuron L, Gummnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. *Neuropsychopharmacology* 2002;26:643–652.
138. Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. *J Clin Oncol* 2003;21:4635–4641.
139. Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. *Breast Cancer Res Treat* 2005;89:243–249.
140. Weitzner MA, Moncello J, Jacobsen PB, et al. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. *J Pain Symptom Manage* 2002;23:337–345.
141. Carpenter JS, Stormiolo AM, Johns S, et al. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. *Oncologist* 2007;12:124–135.
142. Gong S, Sheng P, Jin H, et al. Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis. *PLoS One* 2014;9:e84391.
143. Breitbart W, Alici Y. Psychostimulants for cancer-related fatigue. *J Natl Compr Cancer Netw* 2010;8:933–942.
144. Yennurajalingam S, Palmer JL, Chacko R, et al. Factors associated with response to methylphenidate in advanced cancer patients. *Oncologist* 2011;16:246–253.
145. Bruera E, Strasser F, Shen L, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. *J Pain Symptom Manage* 2003;26:1049–1054.
146. Shaw EG, Rosdhal R, D'Agostino RB Jr, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. *J Clin Oncol* 2006;24:1415–1420.
147. Cullum JL, Wojcickowski AE, Pelletier G, et al. Bupropion sustained release treatment reduces fatigue in cancer patients. *Can J Psychiatry* 2004;49:139–144.
148. Moss EL, Simpson JS, Pelletier G, et al. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. *Psychooncology* 2006;15:259–267.
149. Bruera E, El Osta B, Valero V, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. *J Clin Oncol* 2007;25:3475–3481.
150. Blackhall L, Petroni G, Shu J, et al. A pilot study evaluating the safety and efficacy of modafinil for cancer-related fatigue. *J Palliat Med* 2009;12:433–439.
151. Cooper MR, Bird HM, Steinberg M. Efficacy and safety of modafinil in the treatment of cancer-related fatigue. *Ann Pharmacotherapy* 2009;43:721–725.
152. Kohli S, Fisher SG, Tra Y, et al. The effect of modafinil on cognitive function in breast cancer survivors. *Cancer* 2009;115:2605–2616.
153. Spathis A, Dhillan R, Booden D, et al. Modafinil for the treatment of fatigue in lung cancer: a pilot study. *Palliat Med* 2009;23:325–331.
154. Gupta SC, Kim JH, Kannappan R, et al. Role of nuclear factor kappaB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. *Exp Biol Med (Maywood)* 2011;236:658–671.
155. Lesser GJ, Case D, Stark N, et al. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. *J Support Oncol* 2013;11:31–42.
156. Sood A, Barton DL, Bauer BA, et al. A critical review of complementary therapies for cancer-related fatigue. *Integr Cancer Therapies* 2007;6:8–13.
157. Cruciani RA, Dvorkin E, Homel P, et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. *Ann N Y Acad Sci* 2004;1033:168–176.
158. Cruciani RA, Dvorkin E, Homel P, et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase III study. *J Pain Symptom Manage* 2006;32:551–559.
159. Gramignano G, Lusso MR, Madeddu C, et al. Efficacy of L-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. *Nutrition* 2006;22:136–145.
160. Graziano F, Bisonni R, Catalano V, et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anemic cancer patients. *Br J Cancer* 2002;86:1854–1857.
161. Cruciani RA, Dvorkin E, Homel P, et al. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. *J Pain Symptom Manage* 2009;37:622–631.
162. Cruciani RA, Zhang JJ, Manola J, et al. L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. *J Clin Oncol* 2012;30:3864–3869.
163. de Oliveira Campos MP, Riechelmann R, Martins LC, et al. Guarana (*Paullinia cupana*) improves fatigue in breast cancer patients undergoing systemic chemotherapy. *J Altern Complement Med* 2011;17:505–512.
164. da Costa Miranda V, Trufelli DC, Santos J, et al. Effectiveness of guarana (*Paullinia cupana*) for postirradiation fatigue and depression: results of a pilot double-blind randomized study. *J Altern Complement Med* 2009;15:431–433.
165. Barton DL, Liu H, Dakhil SR, et al. Wisconsin Ginseng (*Panax quinquefolius*) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. *J Natl Cancer Inst* 2013;105:1230–1238.
166. Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. *J Clin Oncol* 2013;31:3076–3082.
167. Matsuo N, Yomiya K. Aggravation of fatigue by steroid therapy in terminally ill patients with cancer. *Am J Hosp Palliat Care* 2014;31:341–344.
168. Kamath J, Feinn R, Winokur A. Thyrotropin-releasing hormone as a treatment for cancer-related fatigue: a randomized controlled study. *Support Care Cancer* 2012;20:1745–1753.
169. Vignano A, Piccioni M, Trutschnigg B, et al. Male hypogonadism associated with advanced cancer: a systematic review. *Lancet Oncol* 2010;11:679–684.
170. Del Fabbro E, Garcia JM, Dev R, et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. *Support Care Cancer* 2013;21:2599–2607.
171. Eton DT, Cella D. Do erythropoietic-stimulating agents relieve fatigue? A review of reviews. *Cancer Treat Res* 2011;157:181–194.
172. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer—meta-analysis based on individual patient data. *Cochrane Database Syst Rev* 2009;CD007303.
173. Bohlius J, Tonia T, Schwarzer G. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients. *Acta Haematologica* 2011;125:55–67.
174. Tonia T, Bohlius J. Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients. *Cancer Treat Res* 2011;157:217–238.
175. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. *Cochrane Database Syst Rev* 2012;12:CD003407.
176. Tonia T, Schwarzer G, Bohlius J. Cancer, meta-analysis and reporting biases: the case of erythropoiesis-stimulating agents. *Swiss Med Wkly* 2013;143:w13776.
177. Grant MD, Piper M, Bohlius J, et al. *Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update*. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
178. Boulaamane L, Goncalves A, Boutayeb S, et al. Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review. *Support Care Cancer* 2013;21:2359–2369.
179. Cancer- and chemotherapy-induced anemia (version 3.2014). National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf.
180. Lichtin AE. Clinical practice guidelines for the use of erythropoietin-stimulating agents: ASCO, EORTC, NCCN. *Cancer Treat Res* 2011;157:239–248.
181. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. *J Clin Oncol* 2010;28:4996–5010.
182. FDA drug safety communication: Erythropoiesis-stimulating agents (ESAs): Procrit, Epogen and Aranesp. U.S. Food and Drug Administration Web site. <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109375.htm>. Accessed January 1, 2014.
183. Bormanis J, Quirt I, Chang J, et al. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)? *Crit Rev Oncol Hematol* 2013;87:132–139.

184. Gao S, Ma JJ, Lu C. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis. *Tumour Biol* 2014;35:603–613.
185. Wauters I, Vansteenkiste J. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy. *Expert Rev Anticancer Ther* 2012;12:1383–1390.
186. Eickmeyer SM, Gamble GL, Shahpar S, et al. The role and efficacy of exercise in persons with cancer. *PM R* 2012;4:874–881.
187. Mustian KM, Sprod LK, Janelins M, et al. Exercise recommendations for cancer-related fatigue, cognitive impairment, sleep problems, depression, pain, anxiety, and physical dysfunction: a review. *Oncol Hematol Rev* 2012;8:81–88.
188. van Haren IE, Timmerman H, Potting CM, et al. Physical exercise for patients undergoing hematopoietic stem cell transplantation: systematic review and meta-analysis of randomized controlled trials. *Phys Ther* 2013;93:514–528.
189. Persoon S, Kersten MJ, van der Weiden K, et al. Effects of exercise in patients treated with stem cell transplantation for a hematologic malignancy: a systematic review and meta-analysis. *Cancer Treat Rev* 2013;39:682–690.
190. Humpel N, Iverson DC. Review and critique of the quality of exercise recommendations for cancer patients and survivors. *Support Care Cancer* 2005;13:493–502.
191. Wolin KY, Schwartz AL, Matthews CE, et al. Implementing the exercise guidelines for cancer survivors. *J Support Oncol* 2012;10:171–177.
192. Strong V, Waters R, Hibberd C, et al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. *Lancet* 2008;372:40–48.
193. Gielissen MF, Wiborg JF, Verhagen CA, et al. Examining the role of physical activity in reducing postcancer fatigue. *Support Care Cancer* 2012;20:1441–1447.
194. Savard J, Simard S, Giguere I, et al. Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects. *Palliat Support Care* 2006;4:219–237.
195. Levesque M, Savard J, Simard S, et al. Efficacy of cognitive therapy for depression among women with metastatic cancer: a single-case experimental study. *J Behav Ther Exp Psychiatry* 2004;35:287–305.
196. Jacobsen PB, Donovan KA, Vadaparampil ST, et al. “Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue”: Correction. *Health Psychol* 2008;27:42.
197. Wanchai A, Armer JM, Stewart BR. Nonpharmacologic supportive strategies to promote quality of life in patients experiencing cancer-related fatigue: a systematic review. *Clin J Oncol Nurs* 2011;15:203–214.
198. Dirksen SR, Epstein DR. Efficacy of an insomnia intervention on fatigue, mood and quality of life in breast cancer survivors. *J Adv Nurs* 2008;61:664–675.
199. Espie CA, Fleming L, Cassidy J, et al. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. *J Clin Oncol* 2008;26:4651–4658.
200. Prinsen H, Bleijenberg C, Heijmen L, et al. The role of physical activity and physical fitness in postcancer fatigue: a randomized controlled trial. *Support Care Cancer* 2013;21:2279–2288.
201. Ritterband LM, Bailey ET, Thorndike FP, et al. Initial evaluation of an Internet intervention to improve the sleep of cancer survivors with insomnia. *Psychooncology* 2012;21:695–705.
202. Zee PC, Ancoli-Israel S. Does effective management of sleep disorders reduce cancer-related fatigue? *Drugs* 2009;69:29–41.
203. Jeste N, Liu L, Rissling M, et al. Prevention of quality-of-life deterioration with light therapy is associated with changes in fatigue in women with breast cancer undergoing chemotherapy. *Qual Life Res* 2013;22:1239–1244.
204. Ancoli-Israel S, Rissling M, Neikrug A, et al. Light treatment prevents fatigue in women undergoing chemotherapy for breast cancer. *Support Care Cancer* 2012;20:1211–1219.
205. Neikrug AB, Rissling M, Trofimenko V, et al. Bright light therapy protects women from circadian rhythm desynchronization during chemotherapy for breast cancer. *Behav Sleep Med* 2012;10:202–216.
206. van Weert E, Hoekstra-Weebers J, Otter R, et al. Cancer-related fatigue: predictors and effects of rehabilitation. *Oncologist* 2006;11:184–196.
207. Strauss-Blasche G, Gnad E, Ekmekcioglu C, et al. Combined inpatient rehabilitation and spa therapy for breast cancer patients: effects on quality of life and CA 15-3. *Cancer Nurs* 2005;28:390–398.
208. Korstjens I, Mesters I, van der Peet E, et al. Quality of life of cancer survivors after physical and psychosocial rehabilitation. *Eur J Cancer Prev* 2006;15:541–547.
209. Heim ME, v d Malsburg ML, Niklas A. Randomized controlled trial of a structured training program in breast cancer patients with tumor-related chronic fatigue. *Onkologie* 2007;30:429–434.
210. Gagnon B, Murphy J, Eades M, et al. A prospective evaluation of an interdisciplinary nutrition-rehabilitation program for patients with advanced cancer. *Curr Oncol* 2013;20:310–318.
211. Chevillat AL, Girardi J, Clark MM, et al. Therapeutic exercise during outpatient radiation therapy for advanced cancer: Feasibility and impact on physical well-being. *Am J Phys Med Rehabil* 2010;89:611–619.
212. van Weert E, Hoekstra-Weebers JE, May AM, et al. The development of an evidence-based physical self-management rehabilitation programme for cancer survivors. *Patient Educ Couns* 2008;4:4.
213. Egan MY, McEwen S, Sikora L, et al. Rehabilitation following cancer treatment. *Disabil Rehabil* 2013;35:2245–2258.
214. Scott DA, Mills M, Black A, et al. Multidimensional rehabilitation programmes for adult cancer survivors. *Cochrane Database Syst Rev* 2013;3:CD007730.
215. Brown P, Clark MM, Atherton P, et al. Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer? *Am J Clin Oncol* 2006;29:52–58.
216. Elam JL, Carpenter JS, Shu XO, et al. Methodological issues in the investigation of ginseng as an intervention for fatigue. *Clin Nurse Spec* 2006;20:183–189.
217. Kiecolt-Glaser JK, Bennett JM, Andridge R, et al. Yoga’s impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial. *J Clin Oncol* 2014;32:1040–1049.
218. Bower JE, Garet D, Sternlieb B, et al. Yoga for persistent fatigue in breast cancer survivors: a randomized controlled trial. *Cancer* 2012;118:3766–3775.
219. Carson JW, Carson KM, Porter LS, et al. Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial. *Support Care Cancer* 2009;17:1301–1309.
220. Carson JW, Carson KM, Porter LS, et al. Yoga for women with metastatic breast cancer: results from a pilot study. *J Pain Symptom Manage* 2007;33:331–341.
221. Moadel AB, Shah C, Wylie-Rosett J, et al. Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life. *J Clin Oncol* 2007;25:4387–4395.
222. Cohen L, Warneke C, Fouladi RT, et al. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. *Cancer* 2004;100:2253–2260.
223. Buffart LM, van Uffelen JC, Riphagen II, et al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. *BMC Cancer* 2012;12:559.
224. Zhang J, Yang KH, Tian JH, et al. Effects of yoga on psychologic function and quality of life in women with breast cancer: a meta-analysis of randomized controlled trials. *J Altern Complement Med* 2012;18:994–1002.
225. Harder H, Parlour L, Jenkins V. Randomised controlled trials of yoga interventions for women with breast cancer: a systematic literature review. *Support Care Cancer* 2012;20:3055–3064.
226. Sadjia J, Mills PJ. Effects of yoga interventions on fatigue in cancer patients and survivors: a systematic review of randomized controlled trials. *Explore (NY)* 2013;9:232–243.
227. Mitchell S, Beck S, Hood L, et al. Putting evidence into practice (PEP): evidence-based interventions for fatigue during and following cancer and its treatment. *Clinical J Oncol Nurs* 2007;11:99.